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Background
The provision of a Quality Assurance Scheme for mem-
bers of the European Malignant Hyperthermia Group
(EMHG) is to ensure that the concentrations of halothane
and caffeine in the tissue bath are as stipulated in the in
vitro contracture test (IVCT) protocol. Confirmation of
the correct concentrations in the tissue bath is an essential
part of the IVCT protocol.
The focus of this presentation will be to provide an
update of the QA results from the analysis of both
halothane and caffeine from all of the participating units
over a period of three years.
The aims are to show
1. How many malignant hyperthermia (MH) units
have achieved the target concentrations of halothane
for nominal vaporiser settings of 0.5% (0.11mM) and
2.0% (0.44mM) and caffeine concentrations of
0.5mM and 2.0mM?
2. How these halothane concentrations can vary
within each lab?
Results
Each lab is aware of its own results. Anonymised results
from January 2012 to January 2014 will be presented
from each participating MH unit.
These will include halothane results for vaporiser set-
tings of 0.5% and 2.0%. The tissue bath concentration is
usually lower than the required concentration, but
halothane concentrations can also be found to be higher.
Halothane concentrations can also vary within each lab.
Caffeine analysis results collected over the past
24 months will also be presented from each participat-
ing lab.
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